Earnings Call Summary | Sera Prognostics(SERA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sera Prognostics(SERA.US) Q1 2024 Earnings Conference
The following is a summary of the Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript:
以下是Sera Prognostics, Inc.（SERA）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Sera Prognostics reported a net revenue of $0 for Q1 2024 due to adjustments as part of their normal revenue recognition process, although gross revenues before adjustments were approximately $39,000.
Total operating expenses for Q1 were $9.1 million, down 20% year-over-year.
The net loss for the quarter decreased 24% to $8.1 million.
The company's cash and available-for-sale securities improved to $85.4 million as of March 2024.
Sera Prognostics報告稱，由於作爲正常收入確認流程的一部分進行了調整，2024年第一季度的淨收入爲0美元，儘管調整前的總收入約爲39,000美元。
第一季度的總運營支出爲910萬美元，同比下降20％。
該季度的淨虧損下降了24％，至810萬美元。
截至2024年3月，該公司的現金和可供出售證券增至8,540萬美元。
Business Progress:
業務進展：
Sera Prognostics is focusing on increasing test adoption and improving product margins.
The company has made progress on strategic priorities like submitting PRIME study findings, improving test analysis process cost-effectiveness, increasing awareness of PreTRM birth, and expanding into international markets.
Shipping of newly validated ambient whole blood collection kits to customers has begun, which is expected to reduce costs and increase patient access.
Plans are in place to share data from their AVERT and PRIME studies with potential international partners and regulators.
The FDA's final rule on Laboratory-Developed Tests (LDTs) is deemed potentially advantageous by the company.
Sera Prognostics專注於提高測試採用率和提高產品利潤率。
該公司在戰略優先事項上取得了進展，例如提交PRIME研究結果，提高測試分析過程的成本效益，提高對preTRM出生的認識以及向國際市場擴張。
新驗證的環境全血採集套件已開始向客戶發貨，預計這將降低成本並增加患者獲得的機會。
已計劃與潛在的國際合作夥伴和監管機構共享其AVERT和PRIME研究的數據。
該公司認爲FDA關於實驗室開發測試（LDT）的最終規則具有潛在的優勢。
More details: Sera Prognostics IR
更多詳情： 紅外血清預測
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。